Despite some promising data, Michael Gilman says company is switching to muscular dystrophy target December 6, 2024Check out STAT+Sponsored By Adobe STAT+ | Arrakis CEO cites 'cul-de-sacs' on road to RNA-intercepting cancer drugs Arrakis was formed with the idea of drugging RNA to fight cancer. Despite some promising data, CEO Michael Gilman is shifting targets. By Jason Mast STAT+ | Inside a Nobel-winning marriage: They see each other as scientific equals, even if the prize committee doesn't Victor Ambros, Nobel Prize winner in medicine, credits crucial contributions from his wife, lab manager, and research co-author Rosalind Lee By Megan Molteni STAT+ | In RFK Jr.'s promise to go after 'big food,' some public health officials see a silver lining Public health experts see an unlikely evangelist for overhauling food policy in RFK Jr. By Adam Piore — Boston Globe More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments